Mike C says UAE, China and India next

[peppy]

Jun 11, 2017 20:51:45 GMT -5 kuka said:

if China and India were not in Play ...he would not have mentioned them. this was a calculated move.

I am ready for this calculated move. so is MNKD share price. You can see the spring is loaded.

4 inside weeks and then last week inside the week before.

Rocket.

www.screencast.com/t/0c9zQtP2ydD9

let's go, let's go, L E T S G O.

[bioexec25]

Ugh where to start. What CEO ids China & India as targets if US not cracked first. If your therapeutic is failing at home then reach out to where there is massive price dilution and generic manufacturing is common place. Dump massive inventory for pennies on the dollar while praying dinosaur docs compensated by pharma somehow start automagically prescribing.

[mango]

Jun 11, 2017 21:07:57 GMT -5 peppy said:

Jun 11, 2017 20:51:45 GMT -5 kuka said:

if China and India were not in Play ...he would not have mentioned them. this was a calculated move.

I am ready for this calculated move. so is MNKD share price. You can see the spring is loaded.

4 inside weeks and then last week inside the week before.

Rocket.

www.screencast.com/t/0c9zQtP2ydD9

let's go, let's go, L E T S G O.

[mango]

A couple of other major issues with injectables, particularly these devices companies call, "pens"—are much more likely to result in device failures and malfunctions, incorrect administration/usage, and inaccurate dosages. These are all issues that, when combined with the significant amount of fear of pain when using them, an inhaled formulation addresses these. 


• March 31, 2017 — Mylan's EpiPen and EpiPen Jr. are recalled. 

The U.S. Food and Drug Administration is alerting consumers to Meridian Medical Technologies’ voluntary recall of 13 lots of Mylan’s EpiPen and EpiPen Jr (epinephrine injection) Auto-Injector products used for emergency treatment of severe allergic reactions. This recall is due to the potential that these devices may contain a defective part that may result in the devices’ failure to activate.

The recalled product was manufactured by Meridian Medical Technologies, a Pfizer company, and distributed by Mylan Specialty between December 2015 and July 2016. The expanded voluntary recall is being initiated in the U.S. and also will extend to additional markets in Europe, Asia, North and South America.

The recall impacts the 0.3 mg and 0.15 mg strengths of EpiPen Auto-Injector. None of the recalled lots include the authorized generic for EpiPen Auto-Injector, which is also manufactured by Meridian Medical Technologies.

www.fda.gov/newsevents/newsroom/pressannouncements/ucm550170.htm


• As of October 26, 2015, Sanofi has received 26 reports of suspected device malfunctions in the US and Canada.

Sanofi US is voluntarily recalling all Auvi-Q (epinephrine injection, USP). The recall involves all Auvi-Q currently on the market and includes both the 0.15 mg and 0.3 mg strengths for hospitals, retailers and consumers. This includes lot number 2299596 through 3037230, which expire March 2016 through December 2016. The products have been found to potentially have inaccurate dosage delivery.

As of October 26, 2015, Sanofi has received 26 reports of suspected device malfunctions in the US and Canada.

www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm470010.htm

[comnkd]

Jun 11, 2017 19:52:49 GMT -5 agedhippie said:

Jun 11, 2017 18:20:11 GMT -5 sportsrancho said:

Maybe he already has. He did say if we didn't get a partner in some TS we could fund ourselves.
He's a doer not a BS'er IMO

To carry a little disposable epinephrine in your pocketbook or something is much easier than carrying a big pen around with you. I’m excited about that product. This could make a big difference for patients. We’re looking at either potential partners to bring that forward, or we’ll fund that ourselves.

I am far more interested in the other drugs than the epinephrine device. My suspicion is that people will stick with the injector in whatever form it comes in (the Auvi-Q looks cute) because it's what they are familiar with. There is always going to be the fear, reasonable or not, that things will happen to fast to inhale properly and injecting removes that. On top I think epi-pens will shortly become a commodity item because so many people seem to be going for the market.

I want to see drugs where there is less competition like their others.

I disagree. My nine year old son has a severe tree nut allergy. I'd rather he wear a necklace with a whistle size inhaler rather than wielding two dagger-sized pens. Plus compliance goes up... suck on a whistle or stab myself in the thigh. Hmmm?

[mango]

Jun 11, 2017 0:56:02 GMT -5 Tinkerbell said:

Well that's not as bad as being called a liar because I didn't have 'the exact' date for the 8K issued in June re: Mike's compensation as new CEO. I was answering your question and didn't realize I had used 'today' instead of June 1st. OK. I could have been corrected but was called a liar instead.

I had my story right about Kent Kresa too. investors.mannkindcorp.com/releasedetail.cfm?ReleaseID=955814

From 2004 through to 2017, Kent and his croonies on this board let Hakan drive this company into the ground and then instead of seeking a new CEO, he handed the reins to Matt.

Yes. That's what Kent did. 

Mike showed up in 2016 of his own accord and Kent had ZERO to do with it. So now, people want to call Kent a genius for replacing Matt with Mike? He's is NO genius board member - no way, no how.

Anyway, glad that Mike is the new CEO and sounding enthusiastic about the future. So now they need to find a younger, go-getter BOARD CHAIRMAN and things should be better set for the future.

I disagree. 


New GM chief Kent Kresa has been here before

While little known outside the aerospace industry, Kresa is considered one of its giants, having transformed a sputtering Los Angeles company on the verge of bankruptcy into one of the world's largest military contractors at the forefront of weapons development.

Kresa, a longtime Los Angeles resident, is expected to preside over the remake of the GM board, but it wasn't clear what role he may have in restructuring the company itself.
In a statement, the Treasury Department said GM was "embarking on a process with the goal of replacing a majority of the board over the coming months." It added that "when complete, these changes will bring fresh thinking and new vision to the company while maintaining a degree of continuity in the current challenging environment."

In a 2002 Times interview, Kresa said Northrop came dramatically close to shutting down altogether. We could just go out of business and give money back to our shareholders or we could reinvent ourselves," Kresa said at the time. After extensive internal studies and heated debates, "it became clear to us we could take the latter path."

He completely transformed Northrop," Thompson said of Kresa. "He changed the products, the market strategy and the culture. In the end, he produced a very successful enterprise that looked nothing like what he had taken over."

Some analysts at the time dubbed Kresa "a stealth CEO," a play on words with Northrop's radar-evading bomber and his shy demeanor that belies an intense competitive streak.

articles.latimes.com/2009/mar/31/business/fi-gm-kresa31


• What do you base your negative claims of Kent Kresa off of besides your personal opinion?

[mango]

Seems to me that, Kent Kresa, being not only a close friend of Al's but the only one with experience in this area (and having done it twice with success and zero times with failure) indeed led the transformation of MannKind.

"Al is a true visionary and has created a great company with an impressive lead product and powerful technology to help patients with serious diseases," said Kent Kresa, Chairman of MannKind Corporation. "We have much to do to make his dreams a reality, but we have the people, technology and know-how to make that happen."

"Al's contribution to the diabetes field is unparalleled, and he truly represents an iconic influence in the philanthropic and business arena for our generation. I'm honored to have worked for so many years with Al, and am proud to have called him my friend," said Kent Kresa, Chairman of the Board of MannKind Corporation.

investors.mannkindcorp.com/releasedetail.cfm?ReleaseID=957439

investors.mannkindcorp.com/releasedetail.cfm?ReleaseID=955814

[falconquest]

So why did Kresa wait until the company nearly collapsed to make a difference? He could have been involved in strategy much sooner than now.

[akemp3000]

Kresa is like a card shark who has been dealt one bad hand after the next, especially the Sanofi card. The game has now changed and good hands are finally coming up often, i.e. Mike C, One Drop, the international strategy and more. Kresa didn't suddenly become un-knowledgeable after being renowned as a brilliant turn-around specialist. We have no way of knowing but it's possible Kresa drove the replacement of Matt with Mike and the new strategy we're seeing now is the result of Kresa and Mike C as a team. It seems to be a good one. We should know soon.

[mnholdem]

Jun 11, 2017 21:30:08 GMT -5 bioexec25 said:

Ugh where to start. What CEO ids China & India as targets if US not cracked first. If your therapeutic is failing at home then reach out to where there is massive price dilution and generic manufacturing is common place. Dump massive inventory for pennies on the dollar while praying dinosaur docs compensated by pharma somehow start automagically prescribing.

It's certainly not the ideal situation, but even lower-margin sales have a big advantage in that, by full or near-full utilization of your production capacity, you drive down the COGS, which helps make up for lower profit margins typical of ex-U.S. sales. With production humming along in high gear, MannKind also is able to lower the price of Afrezza in the USA, so there is somewhat of a silver lining here, IMO.

[madog365]

Jun 12, 2017 7:23:09 GMT -5 mnholdem said:

Jun 11, 2017 21:30:08 GMT -5 bioexec25 said:

Ugh where to start. What CEO ids China & India as targets if US not cracked first. If your therapeutic is failing at home then reach out to where there is massive price dilution and generic manufacturing is common place. Dump massive inventory for pennies on the dollar while praying dinosaur docs compensated by pharma somehow start automagically prescribing.

It's certainly not the ideal situation, but even lower-margin sales have a big advantage in that, by full or near-full utilization of your production capacity, you drive down the COGS, which helps make up for lower profit margins typical of ex-U.S. sales. With production humming along in high gear, MannKind also is able to lower the price of Afrezza in the USA, so there is somewhat of a silver lining here, IMO.

Not to mention the botched launch of exhubera by Pfizer  and later Afrezza by Sanofi significantly affected the perception of docs in the US which is now an uphill battle to correct. I would be interested to see how Afrezza does in a fresh market where no inhaled insulin has ever been sold. It wouldn't surprise me if Afrezza sells much better abroad if given a proper launch.  

[cjm18]

Down big today. The street didn't like mikes interview. Basically it admitted us sales are going to be dismal in the short term.

[madog365]

Jun 12, 2017 8:49:21 GMT -5 cjm18 said:

Down big today. The street didn't like mikes interview. Basically it admitted us sales are going to be dismal in the short term.

doubtful the interview had anything to do with the sp.. this is a normal day in mannkind land. Aren't we currently sitting at the highest short interest of all time? Almost 130M shares pre split and it keeps increasing with over 50% of daily volume shorted each day. These shorts are paying astronomical borrow rates just to get a chance to short some more shares. 

Until we get cash this will continue. 

[mnholdem]

I think that it's also possible that short interests have launched this bear raid today in an attempt to drive the share price as low as possible in order to bail prior to another announcement (or two). Until a PR is released by MannKind there is currently very little buying pressure that would provide much resistance.

As I mentioned this weekend, CEO Castagna's comment about UAE indicates that the rumor originated via a leak somewhere. That could also suggest that a partnership announcement is coming soon, IMO.

Others, of course, will also see this dip as a good opportunity to buy MNKD.

[hans]

I'm so looking forward to that announcement. Thanks, )